Your browser is no longer supported. Please, upgrade your browser.
UTHR United Therapeutics Corporation weekly Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E9.24 EPS (ttm)14.22 Insider Own0.10% Shs Outstand45.43M Perf Week-0.26%
Market Cap5.97B Forward P/E11.97 EPS next Y10.98 Insider Trans-44.74% Shs Float44.32M Perf Month0.95%
Income656.80M PEG- EPS next Q3.65 Inst Own94.00% Short Float19.40% Perf Quarter8.37%
Sales1.60B P/S3.73 EPS this Y19.90% Inst Trans0.00% Short Ratio15.23 Perf Half Y-14.39%
Book/sh46.66 P/B2.82 EPS next Y-24.10% ROA28.10% Target Price125.09 Perf Year14.40%
Cash/sh25.45 P/C5.16 EPS next 5Y- ROE34.50% 52W Range110.72 - 169.89 Perf YTD-8.42%
Dividend- P/FCF8.54 EPS past 5Y33.00% ROI38.40% 52W High-22.68% Beta1.52
Dividend %- Quick Ratio3.30 Sales past 5Y16.60% Gross Margin94.60% 52W Low18.64% ATR2.51
Employees750 Current Ratio3.50 Sales Q/Q0.40% Oper. Margin60.10% RSI (14)55.27 Volatility1.44% 2.03%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.50% Profit Margin41.00% Rel Volume0.75 Prev Close131.25
ShortableYes LT Debt/Eq0.00 EarningsJul 27 BMO Payout0.00% Avg Volume564.47K Price131.36
Recom3.20 SMA200.06% SMA502.97% SMA200-2.22% Volume423,693 Change0.08%
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Jul-19-17 10:56AM  Upcoming Catalysts Could Boost United Therapeutics: OpCo Barrons.com
Jul-12-17 09:30AM  E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day Zacks
Jul-07-17 05:44PM  7 of the Worst-Performing Stocks in Gurus' Portfolios GuruFocus.com
Jul-04-17 10:37AM  What Analysts Recommend for United Therapeutics in June 2017 Market Realist
09:16AM  Cardiome's Partner SteadyMed Submits NDA for PAH Injection Zacks
09:08AM  Adcirca May Witness Gradual Decline in Revenues Market Realist
07:38AM  United Therapeutics Orenitram May Show Revenue Growth in 2017 Market Realist
Jul-03-17 10:39AM  What Can We Expect from United Therapeutics Tyvaso in 2017? Market Realist
09:10AM  How Is United Therapeutics Remodulin Positioned in 2017? Market Realist
07:42AM  How United Therapeutics Is Expected to Perform in 2017 Market Realist
Jun-24-17 12:15AM  [$$] Biotech Blazes Higher Barrons.com
Jun-20-17 06:06PM  Argan and Sturm Ruger Show High Profit and Low Debt GuruFocus.com
Jun-14-17 01:20PM  Silver Spring tissue regeneration company raises $12 million American City Business Journals
Jun-09-17 09:38AM  Your first trade for Friday, June 9 CNBC
Jun-08-17 05:59PM  Fast Money final trades: KSU, SNAP, and more CNBC Videos
Jun-07-17 05:39PM  Here's how the founder of X Prize says you can invest in ... CNBC Videos
Jun-02-17 02:36PM  ETFs with exposure to United Therapeutics Corp. : June 2, 2017 Capital Cube
08:42AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : June 2, 2017 Capital Cube
May-31-17 06:00AM  United Therapeutics Corporation To Present At Jefferies 2017 Global Healthcare Conference PR Newswire
May-19-17 06:50AM  United Therapeutics reworks deal ahead of a key patent's expiration American City Business Journals
May-16-17 08:15AM  Blog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy Accesswire
May-15-17 04:50PM  ETFs with exposure to United Therapeutics Corp. : May 15, 2017 Capital Cube
May-12-17 08:30AM  SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-02-17 04:48PM  ETFs with exposure to United Therapeutics Corp. : May 2, 2017 Capital Cube
May-01-17 10:27AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 Capital Cube
10:02AM  United Therapeutics' Martine Rothblatt saw pay jump last year amid executive shakeup American City Business Journals
Apr-28-17 11:51AM  United Therapeutics partners with 3-D printer to make human organs American City Business Journals
08:00AM  Edited Transcript of UTHR earnings conference call or presentation 26-Apr-17 1:00pm GMT Thomson Reuters StreetEvents
Apr-27-17 08:00PM  United Therapeutics Announces $250 Million Share Repurchase Program PR Newswire
11:29AM  United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss Zacks
08:15AM  Blog Coverage3D Systems and United Therapeutics Partner to Develop 3D Bioprinted Lungs Accesswire
Apr-26-17 03:39PM  These Greater Washington companies may be most affected by Trump's tax reform American City Business Journals
12:32PM  3D Systems signs 'bioprinting' agreement to eventually create human organs American City Business Journals
06:10AM  United Therapeutics beats 1Q profit forecasts Associated Press
06:00AM  United Therapeutics Corporation Reports First Quarter 2017 Financial Results PR Newswire
06:00AM  3D Systems and United Therapeutics Announce Bioprinting Agreement PR Newswire
Apr-25-17 06:50AM  Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Zacks
Apr-19-17 03:58PM  Rising Revenue and Earnings: Mistubishi Financial, United Therapeutics GuruFocus.com
06:00AM  United Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Opens On Wednesday, April 26, 2017 PR Newswire
Apr-18-17 08:30AM  PolarityTE(TM), Inc. Recruits Key Additions to Management Marketwired
Apr-17-17 01:03PM  5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates Zacks
Apr-04-17 10:31AM  Company News for April 04, 2017 Zacks
10:31AM  Company News for April 04, 2017
07:02AM  United Therapeutics Tanks, Remodulin Pump Launch Delayed Zacks
07:02AM  United Therapeutics Tanks, Remodulin Pump Launch Delayed
Apr-03-17 04:52PM  Why DryShips, United Therapeutics, and Fiat Chrysler Automobiles Slumped Today Motley Fool -8.44%
04:52PM  Why DryShips, United Therapeutics, and Fiat Chrysler Automobiles Slumped Today at Motley Fool
11:55AM  SteadyMed Wins Patent Challenge Vs United Therapeutics Investopedia
11:55AM  SteadyMed Wins Patent Challenge Vs United Therapeutics at Investopedia
10:08AM  United Therapeutics shares fall after regulatory delays push back product launch CNBC
10:08AM  United Therapeutics shares fall after regulatory delays push back product launch at CNBC
10:07AM  United Therapeutics loses challenge to its drug patent at bizjournals.com
10:07AM  United Therapeutics loses challenge to its drug patent American City Business Journals
09:42AM  Stocks Open Higher; United Therapeutics Dives Investor's Business Daily
09:42AM  Stocks Open Higher; United Therapeutics Dives
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma TheStreet.com
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma
08:00AM  Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review CNW Group
06:56AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
06:00AM  United Therapeutics Announces Regulatory Delays For Remosynch Implantable Pump PR Newswire
Mar-31-17 01:40PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
01:15PM  United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents PR Newswire
Mar-30-17 09:24AM  Coverage initiated on United Therapeutics by UBS
Mar-28-17 02:43AM  Why Is United Therapeutics (UTHR) Down 5.6% Since the Last Earnings Report?
Mar-21-17 10:05AM  Is United Therapeutics a Great Stock for Value Investors?
Mar-20-17 07:25AM  How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma PR Newswire
Mar-17-17 11:03AM  3 Drug Stocks With Some of the Highest Profit Margins at Motley Fool
Mar-16-17 02:01PM  United Therapeutics Stock Slumping on Credit Suisse Rating
Mar-09-17 06:00AM  Northwell Health and United Therapeutics Announce Strategic Partnership to Advance Bioelectronic Medicine and Cell Therapy PR Newswire
Mar-07-17 06:00AM  United Therapeutics Corporation To Present At Barclays Global Healthcare Conference PR Newswire
Feb-28-17 10:36AM  Will Alexions Research Make Gains in the Inhibitor Space?
09:09AM  Alnylam Pharmaceuticals Advances Its Patisiran Research Program
06:00AM  United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference PR Newswire
Feb-25-17 01:04PM  UNITED THERAPEUTICS CORP Financials
Feb-24-17 02:06PM  Vertex Expects Modest Revenue Growth in This
Feb-23-17 05:39PM  United Therapeutics feels squeeze from increased pulmonary hypertension competition at bizjournals.com
11:36AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
09:18AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
09:03AM  United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
Feb-22-17 05:08PM  Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation at Motley Fool -12.47%
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
06:43AM  United Therapeutics beats 4Q profit forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:08AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report
06:00AM  United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results PR Newswire
Feb-15-17 06:00AM  United Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before The Market Opens On Wednesday, February 22, 2017 PR Newswire
Feb-07-17 02:39PM  Your Guide To 2017's Emerging Pharmaceuticals Catalysts
Feb-03-17 06:27AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-30-17 06:06AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com -6.35%
03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-05-17 08:27AM  New Strong Buy Stocks for January 5th
06:00AM  United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-16 01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
10:10AM  United Therapeutics' PAH Suite Bodes Well, Competition Rife
09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
07:36AM  United Therapeutics Robust Research Pipeline
Dec-28-16 02:05PM  United Therapeutics: Will Orenitram See Strong Patient Demand?
12:35PM  United Therapeutics: Why Tyvaso Is Still a Key Growth Driver
10:55AM  Why United Therapeutics Expects Strong Revenue Growth
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOJul 13Option Exercise30.751,23838,0691,378Jul 14 04:48 PM
ROTHBLATT MARTINE AChairman & CEOJul 13Option Exercise30.7593828,844665,004Jul 14 04:48 PM
ROTHBLATT MARTINE AChairman & CEOJul 13Sale130.441,238161,486140Jul 14 04:48 PM
DWEK RAYMONDDirectorJul 06Option Exercise51.772,000103,5402,000Jul 07 04:09 PM
CAUSEY CHRISTOPHERDirectorJul 06Option Exercise54.7775041,0784,625Jul 07 04:10 PM
MAHON PAUL AEVP & General CounselJul 06Option Exercise54.746,000328,45041,426Jul 07 04:11 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Option Exercise30.751,23437,9461,374Jul 07 04:12 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Option Exercise30.7594328,997664,066Jul 07 04:12 PM
CAUSEY CHRISTOPHERDirectorJul 06Sale132.6159078,2403,875Jul 06 04:26 PM
ROTHBLATT MARTINE AChairman & CEOJul 06Sale132.291,234163,247140Jul 07 04:12 PM
Giltner RichardDirectorJul 05Sale131.123,490457,6090Jul 05 06:25 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Option Exercise30.7593928,874663,123Jun 30 04:27 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Option Exercise30.751,23738,0381,377Jun 30 04:27 PM
ROTHBLATT MARTINE AChairman & CEOJun 29Sale130.921,237161,948140Jun 30 04:27 PM
DWEK RAYMONDDirectorJun 23Sale131.713,490459,6680Jun 23 04:04 PM
ROTHBLATT MARTINE AChairman & CEOJun 22Option Exercise30.7594328,997662,184Jun 23 08:26 AM
ROTHBLATT MARTINE AChairman & CEOJun 22Option Exercise30.751,23437,9461,374Jun 23 08:26 AM
ROTHBLATT MARTINE AChairman & CEOJun 22Sale132.321,234163,282140Jun 23 08:26 AM
SULLIVAN LOUIS WDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:14 PM
Giltner RichardDirectorJun 21Option Exercise0.003,49003,490Jun 22 04:13 PM
DWEK RAYMONDDirectorJun 21Option Exercise0.003,49003,490Jun 22 04:11 PM
Olian Judy D.DirectorJun 21Option Exercise0.003,49003,490Jun 22 04:12 PM
CAUSEY CHRISTOPHERDirectorJun 21Option Exercise0.003,49004,465Jun 22 04:09 PM
PATUSKY CHRISTOPHERDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:10 PM
KURZWEIL RAYDirectorJun 21Option Exercise0.001,75001,750Jun 22 04:08 PM
Thompson Tommy GDirectorJun 21Option Exercise14.832,40035,6012,400Jun 22 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJun 15Option Exercise30.751,23838,0691,378Jun 19 08:21 AM
ROTHBLATT MARTINE AChairman & CEOJun 15Option Exercise30.7593828,844661,241Jun 19 08:21 AM
MAHON PAUL AEVP & General CounselJun 15Option Exercise51.376,000308,22041,426Jun 19 08:22 AM
ROTHBLATT MARTINE AChairman & CEOJun 15Sale130.201,238161,193140Jun 19 08:21 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Option Exercise30.751,24038,1301,380Jun 09 08:27 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Option Exercise30.7593728,813660,303Jun 09 08:27 AM
ROTHBLATT MARTINE AChairman & CEOJun 08Sale129.601,240160,699140Jun 09 08:27 AM
CAUSEY CHRISTOPHERDirectorJun 01Option Exercise54.7775041,0781,725Jun 02 04:19 PM
MAHON PAUL AEVP & General CounselJun 01Option Exercise51.376,000308,22041,426Jun 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Option Exercise30.751,25138,4681,391Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Option Exercise30.7592528,444659,366Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOJun 01Sale125.021,251156,405140Jun 02 04:22 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Option Exercise30.7591228,044658,441May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Option Exercise30.751,26538,8991,405May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 25Sale119.401,265151,039140May 26 04:04 PM
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.751,26138,7761,401May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.7591528,136657,529May 22 09:27 AM
MAHON PAUL AEVP & General CounselMay 18Option Exercise51.376,000308,22041,426May 22 09:29 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Sale120.721,261152,225140May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.751,25938,7141,399May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.7591828,229656,614May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Sale122.001,259153,599140May 15 09:32 AM
MAHON PAUL AEVP & General CounselMay 04Option Exercise51.376,000308,22041,426May 05 04:07 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Option Exercise30.751,25838,6841,398May 05 04:09 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Option Exercise30.7591828,229655,696May 05 04:09 PM
CAUSEY CHRISTOPHERDirectorMay 04Option Exercise53.571,25066,9631,725May 05 04:08 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Sale122.241,258153,774140May 05 04:09 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Option Exercise30.751,26238,8071,402Apr 28 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Option Exercise30.7591528,136654,778Apr 28 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Sale120.781,262152,422140Apr 28 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Option Exercise30.7591628,167653,863Apr 21 05:51 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Option Exercise30.751,26038,7451,400Apr 21 05:51 PM
MAHON PAUL AEVP & General CounselApr 20Option Exercise51.376,000308,22041,426Apr 21 05:50 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Sale121.141,260152,633140Apr 21 05:51 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Option Exercise30.751,25838,6841,398Apr 14 04:08 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Option Exercise30.7591928,259652,947Apr 14 04:08 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Sale122.121,258153,625140Apr 14 04:08 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Option Exercise30.7591928,259652,028Apr 10 04:18 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Option Exercise30.751,25738,6531,397Apr 10 04:18 PM
MAHON PAUL AEVP & General CounselApr 06Option Exercise51.376,000308,22041,426Apr 10 04:17 PM
CAUSEY CHRISTOPHERDirectorApr 06Option Exercise53.571,25066,9631,725Apr 10 04:13 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Sale122.391,257153,848140Apr 10 04:18 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Option Exercise30.751,23037,8231,370Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Option Exercise30.7594729,120651,109Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Sale134.561,230165,509140Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Option Exercise30.751,21937,4841,359Mar 27 04:14 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Option Exercise30.7595729,428650,162Mar 27 04:14 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Sale139.331,219169,842140Mar 27 04:14 PM
Thompson Tommy GDirectorMar 22Option Exercise54.772,000109,5402,000Mar 23 04:26 PM
Thompson Tommy GDirectorMar 22Sale139.372,000278,7400Mar 23 04:26 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Option Exercise30.751,21837,4541,358Mar 20 04:44 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Option Exercise30.7595929,489649,205Mar 20 04:44 PM
MAHON PAUL AEVP & General CounselMar 16Option Exercise51.376,000308,22041,426Mar 20 04:45 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Sale140.161,218170,709140Mar 20 04:44 PM
ROTHBLATT MARTINE AChairman & CEOMar 09Option Exercise30.751,20637,0851,346Mar 13 09:24 AM
ROTHBLATT MARTINE AChairman & CEOMar 09Option Exercise30.7597029,828648,246Mar 13 09:24 AM
PATUSKY CHRISTOPHERDirectorMar 09Option Exercise48.113,000144,3303,000Mar 13 09:25 AM
ROTHBLATT MARTINE AChairman & CEOMar 09Sale146.721,206176,949140Mar 13 09:24 AM
ROTHBLATT MARTINE AChairman & CEOMar 02Option Exercise30.751,20336,9921,343Mar 03 05:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 02Option Exercise30.7597429,951647,276Mar 03 05:02 PM
MAHON PAUL AEVP & General CounselMar 02Option Exercise51.376,000308,22041,221Mar 03 05:03 PM
CAUSEY CHRISTOPHERDirectorMar 02Option Exercise53.571,25066,9631,725Mar 03 05:07 PM
ROTHBLATT MARTINE AChairman & CEOMar 02Sale148.491,203178,632140Mar 03 05:02 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.7596829,766646,302Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.751,20837,1461,348Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Sale145.161,208175,356140Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,00430,873645,334Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,17336,0701,313Feb 17 04:54 PM
MAHON PAUL AEVP & General CounselFeb 16Option Exercise51.376,000308,22041,221Feb 17 04:55 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Sale167.921,173196,966140Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.7599830,689644,330Feb 13 05:21 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.751,17836,2241,318Feb 13 05:21 PM
CAUSEY CHRISTOPHERDirectorFeb 02Option Exercise53.571,25066,9632,225Feb 03 04:14 PM
ROTHBLATT MARTINE AChairman & CEOFeb 02Option Exercise30.751,18136,3161,321Feb 03 04:17 PM